5Shibuya K,Mathers CD,Boschi-Pinto C, et al.Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000[J] .BMC Cancer,2002,2(1) :37.
6Stanley M. Papillomavirus: biology and clinical implication for immunotherapy[J]. Mol Med Roday, 1997, 3(6) :239.
7Huh JJ, Wolf JK, Fightmaster DL, et al. Trandsduction of adenovirusmediated wild-type p53 after radiotherapy in human cervical cancer cells [ J ]. Gynecol Oncol, 2003,89 (2):243-250.
8Bilsland AE, Anderson C J, Flectcher Monagban A J, et al. Selective ablation of human cancer cells by elomerase-specific adenoviral suicide gene theraphy vectors expressing bacterial nitroreductase [J]. Oncogene, 2003,22(3):370-380.
9Tindle RW. Immune cvasion in human papillomavirus-associated cervical cancer[ J]. Nat Rev Cancer, 2002,2 ( 1 ) : 59-65.
10Heinenmnn L, Dillon S, Crawford A, et al. Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a humanpapillomavirus type 16 murine challenge model[J]. J Virol Methods,2004,117(1) :9-18.
